Organization aims to reprogram psilocybin mushrooms in UN categorization
The International Therapeutic Therapeutic Psilocybin Rescheduling Initiative (ITPRI) launched a campaign on January 11 to see medical mushroom reform happen globally.
The organization maintains that the old 1971 law on the United Nations Convention on Psychotropic Substances is long overdue for some changes. While the law was created to target harmful drugs, ITPRI argues that recent evidence for therapy and the effectiveness of psilocybin warrants a change in the schedule.
“In most countries, legal control of psilocybin results from its Schedule I status under the 1971 Convention on Psychotropic Substances,” ITPRI wrote in a press release. “Intended for dangerous drugs which create a particularly serious risk to public health and whose therapeutic value is low or zero, Schedule I drugs are subject to strict limits as to their scientific and medical use.” Restrictions on licensing, safekeeping, security, manufacture, quantity and import / export in Annex I result in a level of regulatory control and oversight that is considerably more onerous than for the other three annexes of the Convention. As a result, researchers wishing to study psilocybin face numerous regulatory hurdles that dramatically increase the cost, complexity, and duration of research and can negatively impact ethical approvals, funding, and collaboration.
According to ITPRI, the 1971 United Nations Convention on Psychotropic Substances Act describes a Schedule I substance as “substances the risk of abuse of which constitutes a particularly serious risk to public health and which have therapeutic utility. very limited, even non-existent ”.
Despite the growing potential of psilocybin as a medical treatment, progress has been hampered by the 51-year-old UN agreement. Professor David Nutt, director of the Center for Psychedelic Research at Imperial College London and founder of drug science, described the reverse. “Psilocybin’s Schedule I status has significantly limited – and continues to limit – neuroscience research and the development of treatments for patients.” Drug Science is one of many partners supporting this effort, including the Beckley Foundation, MAPS, Mind Medicine Australia, Nierika AC, Open Foundation, and Osmond Foundation.
ITPRI’s plan is to inspire UN countries to launch a review. “To ensure equity of access to psilocybin as a global public good, ITPRI engages, educates and mobilizes government officials and other stakeholders without the ecosystem of United Nations agencies, member states’ permanent missions and NGOs that will be critical to achieving a review and a change in schedule, ”the organization said of its rescheduling plan. Once the process begins, the World Health Organization (WHO) will present a critical review, which could lead to a recommendation for reprogramming if two-thirds of member countries agree.
ITPRI Co-Founder and Chairman of the Board, Christopher Koddermann, expressed confidence that ITPRI’s new campaign will help move things forward. “Given the current scientific understanding of psilocybin’s high potential therapeutic value and low risk of dependence, a change in its status as a Schedule I drug is long overdue.”
In December 2020, the United Nations Commission on Narcotic Drugs voted to reclassify cannabis, and more recently, the United Nations voted against a ban on kratom in December 2021. In addition, many states and cities in the United States have adopted the decriminalization of fungi to allow medical patients to more easily access psilocybin fungi as a treatment. The state of Oregon was one of the first to adopt the legalization of psilocybin mushrooms.
Companies such as Dr. Bronner’s are doing everything to support the legalization of psilocybin, both in Connecticut and in the United States. Canada has even facilitated access to mushrooms, in part thanks to the growing body of evidence that suggests its potential as a medicine. Last year British Prime Minister Boris Johnson expressed his intention to consider treatment with psilocybin. All of this and more are contributing to the evolution of the world view of psilocybin as a medicine.